An interventional study of GnRH antagonist and Gonadotropins in Invitro Fertilizaion, sponsored by Cairo University. Status unknown at 1 site in Egypt. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2018-04-02.
Sponsored by Cairo University · Not applicable, Interventional, and Diagnostic
A multicentric study looked into 179 poor responders who underwent antagonist protocol in ICSI cycles Gonadotrophines is started on day 2 with HMG until the day of HCG administration with starting dose 300IU to 450IU,with no pretreatment with OCPs or progestogens or estrogen.
GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans vaginal probe to assess the ovarian response till the mature follicles reach18-20mm when hCG administration 10000 IU is given to induce final oocytes maturation , serum E2 is done on day of HCG trigger.
Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG injection.
Ultrasound -guided fresh embryo transfer is performed on day 3 or 5 after fertilization.
Progesterone support of luteal phase was commenced on the day of ovum pick up using prontogest 400 mg twice daily.
A multicentric study looked into 179 poor responders who underwent antagonist protocol in ICSI cycles
Induction of ovulation cycle:
Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any factor which may affect reproductive outcome other than that the patient is a poor responder will be excluded from the study, like:
10.Hepatic or renal dysfunction 11.Hypersenstivity to study medication ( GNRH antagonist) 12.Need to take medication that can influence ovarian stimulation 13.Endometriosis grade 3 or 4 14.Ovarian cyst> 10 cm.
Poor ovarian responders according to ESHRE consensus with serum AMH \< 0,3 ng/ml
Drug: GnRH antagonist · Drug: Gonadotropins · Drug: Human chorionic gonadotropin · Procedure: Embryo transfer · Drug: Progesterone
Poor ovarian responders according to ESHRE consensus with serum AMH 0.3 to 0.7 ng/ml
Drug: GnRH antagonist · Drug: Gonadotropins · Drug: Human chorionic gonadotropin · Procedure: Embryo transfer · Drug: Progesterone
Poor ovarian responders according to ESHRE consensus with serum AMH 0.7 to 1 ng/ml
Drug: GnRH antagonist · Drug: Gonadotropins · Drug: Human chorionic gonadotropin · Procedure: Embryo transfer · Drug: Progesterone
0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
Also known as: cetrorelix
started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU
Also known as: Human menopausal gonadotropin
10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more
Also known as: HCG
0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)
vaginal prontogest 400 mg twice daily
Number of the retrieved oocytes
number of oocytes retrieved 34 hours after HCG injection
Time frame: 34 hours after HCG injection
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gonadotropin Releasing Hormone Antagonist · Gonadotropins · Chorionic Gonadotropin · Progesterone